Status:
COMPLETED
A Study of Lasmiditan in Healthy Chinese Participants
Lead Sponsor:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This is a study of lasmiditan in healthy Chinese participants. The purposes are: * To evaluate the safety of lasmiditan * To learn more about how the body processes lasmiditan The study will last up...
Eligibility Criteria
Inclusion
- Are overtly healthy Chinese (all 4 biological grandparents and both biological parents to be of Chinese origin) males or females, as determined by medical history and physical examination
- Have a body mass index (BMI) of 18.0 to 32.0 kilograms per square meter, inclusive
- Are able and willing to give signed informed consent
Exclusion
- Have known allergies to lasmiditan, related compounds or any components of the formulation
- Have an abnormal blood pressure and/or pulse rate as determined clinically significant by the investigator
- Have a history of, show evidence of, or are undergoing treatment for significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression)
- Have a history of central nervous system (CNS) conditions such as strokes, transient ischemic attack, significant head trauma, CNS infections, migraines, brain surgery, or any other neurological conditions that, in the opinion of the investigator, increases the risk of participating in the study
- Regularly use known drugs of abuse and/or show positive findings on drug screening
Key Trial Info
Start Date :
November 13 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 15 2020
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04081324
Start Date
November 13 2019
End Date
June 15 2020
Last Update
July 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HuaShan Hospital Affiliated To Fudan University
Shanghai, Shanghai Municipality, China, 20040